Drug Profile
Amivantamab - Genmab/Janssen Biotech
Alternative Names: Ami-LC-MD; Amivantamab admixed with rHuPH20; Amivantamab-vmjw; Bispecific EGFR-cMet antibody; CNTO4424; EGFR-MET bispecific antibody; EGFRxcMET bispecific antibody; JNJ 372; JNJ-61186372; JNJ-6372; RYBREVANTLatest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Genmab; Janssen Biotech
- Developer Janssen Biotech; Janssen Research & Development; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Gastric cancer; Liver cancer; Oesophageal cancer
- Phase I/II Colorectal cancer
- Phase I Solid tumours
Most Recent Events
- 01 Mar 2024 Registered for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)
- 26 Feb 2024 Janssen Biotech initiates a phase II COCOON trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease, Inoperable/Unresectable) in USA, Taiwan and Malaysia (IV, Infusion) (NCT06120140) (EudraCT2023-505863-35-00)
- 31 Jan 2024 Jannsen announces intention to submit BLA to US FDA and EMA in Non-small cell lung cancer in 2024